Objective: This study aims to analyze the available data on prevention and early diagnosis in gynecological cancers. Mechanism: A comprehensive search was performed in the PubMed (MEDLINE), EMBASE, SCOPUS and Web of Science databases. Findings in Brief: To date the prevention programmes of all degrees exist exclusively for cervical cancer. Human Papilloma Virus (HPV) vaccination prevents from infection and development of precancerous lesions and contributes significantly to the deflection of the incidence of cervical cancer. Screening for HPV-related lesions is worldwide performed by cervical smear (Pap-test) and HPV test. Finally, tertiary prevention is aimed at the treatment of previously diagnosticated lesions with the aid of surgery, chemotherapy, radiotherapy and immunotherapy. Unfortunately, to date the prevention programmes of other gynecological tumors have not reached a good performance; indeed, the primum movens that leads to the development of such neoplasms has not been identified yet. Actually, no screening programs for the early diagnosis of endometrial cancer are available, however, it is recommended the adoption of a healthy lifestyle and a balanced diet. Diagnostic biomarkers would be helpful for screening asymptomatic high-risk women, but histopatological examinations remain the gold standard for diagnosis of endometrial cancer. Similarly, there are no screening tests for the diagnosis of ovarian cancer. In recent years many steps forward have been made in this field and new perspectives have been presented, however, additional investigation is needed to optimize the duration and timing of treatment, examine its cost-effectiveness, and identify potential tumor or host biologic factors predictive of the efficacy and adverse events. Finally, there are no primary and secondary prevention for vulvar cancer so patients should be invited to self-examination and pay attention to the presence of symptoms. Conclusions: Are the available screening programs for the diagnosis of gynecological carcinomas sufficient? The prevention and the diagnosis of precancerous lesions is the goal to be achieved for all gynecological cancers in order to improve patient outcomes, reduce the costs for managing the disease and prolonged follow up.

Prevention, Screening, Treatment and Follow-Up of Gynecological Cancers. State of Art and Future Perspectives / Golia D( extquotesingle)Aug(`(e)), Tullio; Giannini, Andrea; Bogani, Giorgio; DI DIO, Camilla; Simone Lagan(`(a)), Antonio; DI DONATO, Violante; Giovanna Salerno, Maria; Caserta, Donatella; Chiantera, Vito; Vizza, Enrico; Muzii, Ludovico; D'Oria, Ottavia. - In: CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY. - ISSN 0390-6663. - 50:8(2023), pp. 1-8. [10.31083/j.ceog5008160]

Prevention, Screening, Treatment and Follow-Up of Gynecological Cancers. State of Art and Future Perspectives

Andrea Giannini;Giorgio Bogani;Camilla Di Dio;Violante Di Donato;Donatella Caserta;Ludovico Muzii;Ottavia D'Oria
2023

Abstract

Objective: This study aims to analyze the available data on prevention and early diagnosis in gynecological cancers. Mechanism: A comprehensive search was performed in the PubMed (MEDLINE), EMBASE, SCOPUS and Web of Science databases. Findings in Brief: To date the prevention programmes of all degrees exist exclusively for cervical cancer. Human Papilloma Virus (HPV) vaccination prevents from infection and development of precancerous lesions and contributes significantly to the deflection of the incidence of cervical cancer. Screening for HPV-related lesions is worldwide performed by cervical smear (Pap-test) and HPV test. Finally, tertiary prevention is aimed at the treatment of previously diagnosticated lesions with the aid of surgery, chemotherapy, radiotherapy and immunotherapy. Unfortunately, to date the prevention programmes of other gynecological tumors have not reached a good performance; indeed, the primum movens that leads to the development of such neoplasms has not been identified yet. Actually, no screening programs for the early diagnosis of endometrial cancer are available, however, it is recommended the adoption of a healthy lifestyle and a balanced diet. Diagnostic biomarkers would be helpful for screening asymptomatic high-risk women, but histopatological examinations remain the gold standard for diagnosis of endometrial cancer. Similarly, there are no screening tests for the diagnosis of ovarian cancer. In recent years many steps forward have been made in this field and new perspectives have been presented, however, additional investigation is needed to optimize the duration and timing of treatment, examine its cost-effectiveness, and identify potential tumor or host biologic factors predictive of the efficacy and adverse events. Finally, there are no primary and secondary prevention for vulvar cancer so patients should be invited to self-examination and pay attention to the presence of symptoms. Conclusions: Are the available screening programs for the diagnosis of gynecological carcinomas sufficient? The prevention and the diagnosis of precancerous lesions is the goal to be achieved for all gynecological cancers in order to improve patient outcomes, reduce the costs for managing the disease and prolonged follow up.
2023
gynecologic oncology; cancer prevention; gynecological cancers; hpv vaccination; screening programs
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Prevention, Screening, Treatment and Follow-Up of Gynecological Cancers. State of Art and Future Perspectives / Golia D( extquotesingle)Aug(`(e)), Tullio; Giannini, Andrea; Bogani, Giorgio; DI DIO, Camilla; Simone Lagan(`(a)), Antonio; DI DONATO, Violante; Giovanna Salerno, Maria; Caserta, Donatella; Chiantera, Vito; Vizza, Enrico; Muzii, Ludovico; D'Oria, Ottavia. - In: CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY. - ISSN 0390-6663. - 50:8(2023), pp. 1-8. [10.31083/j.ceog5008160]
File allegati a questo prodotto
File Dimensione Formato  
D_Augè_Prevention-Screening-Treatment-Follow-Up-Gynecological-Cancers_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 247.43 kB
Formato Adobe PDF
247.43 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1690301
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 20
social impact